News - News - MicroPort® CardioFlow

News

Always Share with You
Every Bit of Our Progress

News

2024.04.25

CardioFlow’s VitaFlow Liberty^® Granted EU CE-MDR Mark, Advancing Global Expansion Roadmap

Read More
2024.01.08

MicroPort^® CardioFlow Receives Approval for Its AnchorMan^® LAAC System in China

Read More
2023.12.29

MicroPort^® CardioFlow Completed the First Overseas Clinical Application of TMVR System Under Compassionate Use, with Excellent 30-Day Follow-Up Results

Lille, France - Recently, the Transcatheter Mitral Valve Replacement System ("TMVR System") of MicroPort® CardioFlow Medtech Corporation (hereinafter referred to as " MicroPort® CardioFlow ") has successfully completed its first overseas clinical application under compassionate use at Lille University Center Hospital in France. The procedure, led by Prof. Thomas Modine's team at the hospital, resulted in a stable recovery for the patient, with good hemodynamic improvement, and the patient was discharged after recovery. The 30-day follow-up results showed complete disappearance of mitral regurgitation, no perivalvular leakage, and the valve was in good working order and stable position.

Read More
2023.12.29

MicroPort^® CardioFlow Completed the First Implantation of VitaFlow Liberty^® in Russia

Moscow, Russia- On December 18, 2023, MicroPort® CardioFlow completed the first implantation of its VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty®) in Russia, marking the completion of a highly complex Type 0 bicuspid aortic valve implantation with an extremely horizontally positioned heart via Transcatheter Aortic Valve Implantation (TAVI). Led by Professor Imaev Timur of the Russian National Medical Research Center for Cardiovascular Surgery, with guidance from Chinese experts, the team achieved precise deploy and successful release of the valve without the need for post-dilation. Post-operative echocardiography showed good valve shape and position, with no paravalvular leakage or conduction abnormalities, confirming the success of the procedure.

Read More
2023.12.15

MicroPort^® CardioFlow Receives Approval for Alwide^® Plus in Saudi Arabia

Shanghai, China-Recently, the second-generation balloon catheter-Alwide Plus Balloon Catheter (hereinafter referred to as "Alwide Plus") self-developed by MicroPort® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort® CardioFlow, stock code: 02160.HK) was approved for marketing by Saudi Food & Drug Authority.

Read More

<4 5 6 7 8 9 10 11 12 13 14 >

Privacy settings

This website may store cookies on your browser. Cookies are mostly used to make the website work asyou expect it to. No cookie will directly identify you, but it can give you a more personalized browsingexperience.

CardioFlow Medtech respects your privacy rights, so you can block some types of cookies. Technically non-essentialcookies and tracking mechanisms, that enable us to provide you with customized offers (marketingcookies), are only used if you have given prior consent to such use.

Strictly necessary cookies

Consent to marketing cookies

By clicking "Save", only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings. For more information, please see our Cookie Policy.

TOP

互联网药品信息服务资格证书编号：（沪）-非经营性 - 2024 - 0135

“MicroPort CardioFlow”及“ are registered trademarks of MicroPort CardioFlow Medtech Corporation.